GIANNECCHINI, SIMONE
GIANNECCHINI, SIMONE
Medicina Sperimentale e Clinica
A retro-inverso analogue of the antiviral octapeptide C8 inhibits feline immunodeficiency virus in serum.
2003 A. M. DURSI; S. GIANNECCHINI; A. DI FENZA; C. ESPOSITO; A. CAROTENUTO; M. BENDINELLI; P. ROVERO
A retroinverso peptide reproducing the Trp-rich motif of the FIV TM has favorable pharmacological traits and markedly reduces viral loads in a short-monotherapy experiment.
2005 S. GIANNECCHINI; ALCARO M.C; ISOLA P; SICHI O; PISTELLO M; PAPINI A.M; ROVERO P; BENDINELLI M
A unique domain for a unique target: selective inhibitors of host cell DDX3X to fight emerging viruses
2020 Valentina Riva, Anna Garbelli, Annalaura Brai, Federica Casiraghi, Roberta Fazi, Claudia I Trivisani, Adele Boccuto, Francesco Saladini, Ilaria Vicenti, Francesco Martelli, Maurizio Zazzi, Simone Giannecchini, Elena Dreassi, Maurizio Botta, Giovanni Maga
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine.
1999 P. MAZZETTI; S. GIANNECCHINI; D. DEL MAURO; D. MATTEUCCI; P. PORTINCASA; A. MERICO; C. GHEZZI; AND M. BENDINELLI
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts.
2002 S. GIANNECCHINI; P. ISOLA; O. SICHI; D. MATTEUCCI; M. PISTELLO; L. ZACCARO; D. DEL MAURO; AND M. BENDINELLI
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: homologous erythrocytes as a delivery system for preferential immunization with putative protective antigens.
1998 L. CHIARANTINO; D. MATTEUCCI; M. PISTELLO; U. MANCINI; P. MAZZETTI; C. MASSI; S. GIANNECCHINI; I. LONETTI; M. MAGNANI; AND M. BENDINELLI
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies.
2001 S. GIANNECCHINI; D. DEL MAURO; D. MATTEUCCI; AND M. BENDINELLI
AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus.
1999 D. MATTEUCCI; M. PISTELLO; P. MAZZETTI; S. GIANNECCHINI; P. ISOLA; A. MERICO; L. ZACCARO; A. RIZZUTI AND M. BENDINELLI
Analisi dell’espressione di microRNA prodotti dal Polyomavirus JC.
2013 Simone Giannecchini ; Irene Giovannelli; Valeria Clausi; Anna Repice; Luca Massacesi; Alberta Azzi
Antibodies generated in cats by a lipopeptide reproducing the MPER of the feline immunodeficiency virus TM enhance virus infectivity
2007 S.Giannecchini; A.M.D'Ursi; C.Esposito; M.Scrima; E.Zabogli; G.Freer; P.Rovero; M.Bendinelli
Antiviral activity against SARS-CoV-2 of conformationally constrained helical peptides derived from angiotensin-converting enzyme-2.
2023 Michael Quagliata, Maria Alfreda Stincarelli, Anna Maria Papini, Simone Giannecchini, Paolo Rovero
Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.
2003 S. GIANNECCHINI; A. DI FENZA; A. M. DURSI; D. MATTEUCCI; P. ROVERO; AND M. BENDINELLI
Antiviral activity of oligonucleotides targeting the SARS-CoV-2 genomic RNA stem-loop sequences within the 3’-end of the ORF1b.
2022 Stincarelli MA, Rocca A, Antonelli A, Rossolini GM, Giannecchini S.
Archetype JC polyomavirus DNA associated with extracellular vesicles circulates in human plasma samples.
2020 Stefano Scribano, Mirko Guerrini, Rosaria Arvia, Daniele Guasti, Patrizia Nardini, Paolo Romagnoli, Simone Giannecchini
Are there lessons that can be learned from the FIV model ?
2005 BENDINELLI M; MATTEUCCI D; PISTELLO M; FREER G; S. GIANNECCHINI
Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab
2012 S.Giannecchini; V.Clausi; A.Vultaggio; L.Macera; F.Maggi; F.Martelli; A.Azzi; E.Maggi; A.Matucci
Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates.
1998 D. DEL MAURO; D. MATTEUCCI; S. GIANNECCHINI; F. MAGGI; M. PISTELLO; AND M. BENDINELLI
BK polyomavirus microRNA levels in exosomes are modulated by non-coding control region activity, and down-regulate viral replication when delivered to non-infected cells prior to infection.
2018 Martelli F., Wu Z., Delbue S., Weissbach F.,Giulioli M.C., Ferrante P., Hirsch H.H., Giannecchini S.
Blood levels of TT virus following immune stimulation with influenza or hepatitis B vaccine.
2004 F. MAGGI; E. TEMPESTINI; L. LANINI; E. ANDREOLI; C. FORNAI; S. GIANNECCHINI; M.-L VATTERONI; M. PISTELLO; S. MARCHI; P. CICCOROSSI; S. SPECTER; AND M. BENDINELLI
Changes in the SU can modulate the susceptibility of feline immunodeficiency virus to TM-derived entry inhibitors.
2004 S. GIANNECCHINI; M. PISTELLO; B. DEL SANTO; P. ROVERO; O. SICHI; AND M. BENDINELLI